

## PLADO Publication list

### Original articles

1. Slichter SJ. Background, rationale, and design of a clinical trial to assess the effects of platelet dose on bleeding risk in thrombocytopenic patients. *J Clin Apher* 2006; 21:78-84.
2. Slichter SJ, Kaufman RM, Assmann SF, et al. Dose of Prophylactic Platelet Transfusions and Prevention of Hemorrhage. *N Engl J Med* 2010; 362:600-613.
3. Triulzi DT, Assmann SF, Struass RG, et al. The impact of platelet transfusion characteristics on post-transfusion platelet increments and clinical bleeding in patients with hypo-proliferative thrombocytopenia. *Blood* 2012 Jun 7; 119(23): 5553-62.
4. Josephson C, Granger S, Assmann SF, et al. Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment-induced hypoproliferative thrombocytopenia. *Blood* 2012 Jul 26; 120(4): 748-60.

### Letter to the editor

1. Slichter SJ, Triulzi DJ, Assmann SF. Prophylactic platelet transfusions. *N Engl J Med* 2010; 362: 2142.

### Conference presentations

1. Slichter SJ, Kaufman RM, Assmann SF, Brecher ME, Gernsheimer T, Hillyer CD, McCullough J, Strauss RG, and Triulzi D. Effects of Prophylactic Platelet (Plt) Dose on Transfusion (Tx) Outcomes (PLADO Trial). *Blood* 2008; 112:1111.
2. Blajchman MA, Slichter SJ, Heddle NM, Murphy MF. New strategies for the optimal use of platelet transfusions. *Hematology Am Soc Hematol Educ Program*. 2008; 198-204.
3. Josephson C, Sloan S, Granger S, et al. Increased incidence of Grade 2 and higher bleeding in pediatric PLADO trial patients. *Transfusion* 2009; 49:19A-20A.
4. Triulzi DJ, Assmann S, Strauss RG et al. Characteristics of transfused platelets do not affect bleeding outcomes in hypoproliferative thrombocytopenia. *Blood* 2009; 114:14-14.